Development of a GPCR-binding ligand screening method using real-time interaction analysis on live cells

Hadis Westin, Hanna Yushchyshyna, Olga Vorontsova, Saloni Chopra, Tianqi Xu, Christoffer Bengtsson, Fabio Begnini, Preeti Jha, Ulrika Rosenström, Ulrika Yngve, Marika Nestor, Jos Buijs
Biochemistry and Biophysics Reports · Elsevier · DOI: 10.22541/au.177452855.54796920/v1

Abstract

Background and Purpose: G protein-coupled receptors (GPCRs) affect many physiological processes, and their dysfunction is related to a wide range of diseases and are thus frequently used as drug targets and biomarkers. The present study focuses on the neurokinin 1 receptor (NK1-R) which is over-expressed on neural tumours with the aim to develop high affinity binders to NK1-R for theranostic purposes. 60 Ligands were synthesized, all containing iodine enabling isotopic exchange with radioactive iodine for imaging or radiotherapeutic applications. Experimental Approach: Embedded in the cellular membrane, GPCRs adopt various conformational states that can change upon interaction with agonistic or antagonistic ligands. To screen ligands, a time-resolved, live cell assay was developed to evaluate competition with fluorescently labelled endogenous NK1-R ligand, Substance P (FAM-SP). Key Results: The time resolved assay enabled quantification of the efficiency in which the ligands compete for the rapid and slow releasing NK1-R binding modes of FAM-SP. 25 Ligands were able to displace FAM-SP faster than the anti-nausea drug aprepitant. Two of these ligands displaced the rapid releasing FAM-SP fraction faster than Substance P (SP) and one of them also replaced the slow releasing fraction faster than aprepitant. To validate the assay, the affinity of two ligands for several NK1-R expressing cell lines was further quantified; one that had similar competition characteristics as SP and one that behaved as aprepitant. Conclusion and Implications: The ligand with similar competition characteristics as SP displayed a low nM to sub-pM affinity with a stronger binding correlating with higher receptor expression levels. This high affinity makes it a highly promising candidate for further development into a theranostic agent to address neural tumours.

Read at publisher →

Similar articles